Compare BridgeBio Pharma Inc (BBIO) vs HP Inc (HPQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs HP Inc — how do they compare? BridgeBio Pharma Inc trades at $84.33 (market cap $16.36B), while HP Inc trades at $28.64 (market cap $26.59B). The key difference: HP Inc is the larger of the two by market cap, and HP Inc pays a 4.13% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | HPQ | |
|---|---|---|
Market Cap | $16.36B | $26.59B |
Sector | Health | Technology |
52-Week High | $90.17 | $30.05 |
52-Week Low | $47.29 | $18.20 |
Enterprise Value | $18.14B | $33.75B |
Dividend Yield | — | 4.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.67, up 0.22% today, with a bullish technical signal and strong analyst consensus. Despite missing Q2 2026 EPS estimates with a loss of $0.78 per share, revenue beat expectations as Attruby sales surged 311% year-over-year. The company maintains a high gross margin of 94.44% but reports negative net income and cash flow from operations, reflecting its growth investment phase.
The outlook is optimistic due to multiple late-stage pipeline catalysts, including three potential product launches by mid-2027 and an FDA decision on encaleret by May 2027. Risks include sustained cash burn, high debt of $1.72 billion, and clinical trial execution. The consensus price target of $104.56 implies significant upside if commercial execution succeeds.
HPQ trades at $29.80, down 0.83% on the day, with a bullish technical signal supported by moving averages and positive earnings beats in recent quarters. The company reported Q2 2026 revenue of $14.4B and EPS of $0.86, exceeding expectations, driven by premium product mix and AI-driven efficiencies. Valuation metrics show a P/E of 10.77 and P/S of 0.48, indicating potential undervaluation relative to historical averages.
The outlook remains positive with continued earnings momentum and a 2026 revenue forecast of $57.4B, though risks include PC market volatility and competitive pressures. Analyst consensus is mixed with 29% buy ratings, but technical support at $29 suggests near-term stability. The dividend yield of approximately 4% provides income appeal amid growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About HP Inc
HP Incorporated is a leading provider of computers, printers, and printer supplies. The company's mains segments are personal systems and printing. Its personal systems segment contains notebooks, desktops, and workstations. Its printing segment contains supplies, consumer hardware, and commercial hardware. In 2015, Hewlett-Packard was separated into HP Incorporated and Hewlett Packard Enterprise and the Palo Alto, California-based HP Incorporated sells on a global scale.
Read more on HPQ →
